Core Insights - Annovis Bio Inc. is participating in the 13th Alzheimer's & Parkinson's Drug Development Summit to discuss advancements in treatments for neurodegenerative diseases [1][2] - The company emphasizes the need for a holistic approach to treatment, addressing multiple neurotoxic proteins rather than focusing on a single target [2] Company Overview - Annovis Bio is a late-stage clinical drug platform company based in Malvern, Pennsylvania, dedicated to developing therapies for Alzheimer's disease (AD) and Parkinson's disease (PD) [1][3] - The company aims to improve patient outcomes and quality of life through innovative therapies [3] Event Participation - Annovis will present data from Phase III clinical trials of its drug Buntanetap and participate in a panel discussion on March 19, focusing on new therapeutic approaches for Parkinson's disease [2] - The summit is recognized as a comprehensive industry-focused meeting that covers the entire spectrum of neurodegenerative disease research and development [2]

MALVERN, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Annovis Bio Inc. (NYSE: ANVS) ("Annovis"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), will participate at the 13th Alzheimer’s & Parkinson’s Drug Development Summit happening on March 18-20 in Boston, MA. "This meeting represents an important opportunity to advance our understanding of the next-generation treatment for neurodegene ...

Core Viewpoint - Annovis Bio, Inc. is hosting a live webcast to provide updates on its clinical trials for neurodegenerative diseases, specifically Alzheimer's disease and Parkinson's disease, while addressing questions from patients and caregivers [1][2][3]. Group 1: Webcast Details - The webcast will feature CEO Maria Maccecchini providing updates on the ongoing Phase 3 trial for Alzheimer's disease, as well as plans for the Phase 3 trial for Parkinson's disease and Open Label Extension studies [2]. - A short presentation will highlight recent achievements, followed by a Q&A session where attendees can submit questions in advance [2]. Group 2: Company Mission and Approach - Annovis Bio is focused on addressing neurodegeneration in diseases such as Alzheimer's and Parkinson's, utilizing an innovative approach that targets multiple neurotoxic proteins to restore brain function and improve patients' quality of life [4]. - The company emphasizes transparency and patient-centric communication, aiming to address questions from patients, families, and caregivers [3]. Group 3: Investor Engagement - Investors and shareholders are encouraged to sign up for press releases and industry updates through the company's email alerts [5]. - The updated investor website offers comprehensive access to company news, financial reports, and other key information [5].

Core Viewpoint - Annovis Bio, Inc. is hosting a live webcast to provide updates on its clinical trials for neurodegenerative diseases, specifically Alzheimer's disease and Parkinson's disease, while engaging with patients, caregivers, and families [1][2][3] Group 1: Webcast Details - The webcast will feature CEO Dr. Maria Maccecchini discussing the ongoing Phase 3 trial for Alzheimer's disease, plans for the Phase 3 trial for Parkinson's disease, and patient communication strategies [2] - A short presentation will highlight recent achievements, followed by a Q&A session where attendees can submit questions in advance [2] Group 2: Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, focusing on innovative therapies for neurodegenerative diseases by targeting multiple neurotoxic proteins to restore brain function [4] - The company emphasizes its commitment to transparency and patient engagement, aiming to address questions from current and prospective patients [3] Group 3: Investor Engagement - Investors and shareholders are encouraged to sign up for press releases and industry updates through the company's email alerts [5] - The updated investor website offers comprehensive access to company news, financial reports, and other key information [5]

Core Insights - Annovis Bio Inc. is a late-stage clinical drug platform company focused on developing therapies for neurodegenerative diseases such as Alzheimer's disease and Parkinson's disease [1][4] - The CEO, Dr. Maria Maccecchini, will present at Oppenheimer's 35th Annual Healthcare Life Sciences Conference, discussing the company's advancements and the pivotal Phase 3 trial for its drug, buntanetap [1][2] Company Overview - Annovis Bio is headquartered in Malvern, Pennsylvania, and is dedicated to addressing neurodegeneration in diseases like Alzheimer's and Parkinson's [4] - The company aims to develop innovative therapies that enhance patient outcomes and quality of life [4] Conference Details - The Oppenheimer's Annual Healthcare Life Sciences Conference is a significant event that gathers leading companies and investors in the healthcare and life sciences sectors [3] - The conference features presentations from industry executives, offering insights into current trends, innovations, and investment opportunities [3]

Core Insights - Annovis Bio Inc. has initiated a pivotal Phase 3 study for its drug candidate, buntanetap, targeting early Alzheimer's disease (AD) [1][2] - The study aims to evaluate both symptomatic and potential disease-modifying effects of buntanetap, following promising results from previous trials [2][3] Study Design and Objectives - The Phase 3 trial is a randomized, placebo-controlled, double-blind study lasting 18 months, with a 6-month assessment of symptomatic effects and a subsequent 12-month evaluation of disease-modifying effects [3] - Primary outcomes will include cognitive assessment using the Alzheimer's Disease Assessment Scale-Cognitive 13 (ADAS-Cog13) and functional ability using the Alzheimer's Disease Cooperative Study-Instrumental Activities of Daily Living (ADCS-iADL) scale [6] Funding and Enrollment - The company completed a public offering of 5,250,000 units, raising gross proceeds of $21 million to fund the initial 6-month portion of the study [4] - Annovis plans to enroll over 750 participants across approximately 100 sites in the United States, with initial recruitment sites already operational [7] Drug Mechanism and Potential - Buntanetap is designed to inhibit neurotoxic protein aggregation, improving axonal transport and reducing neuroinflammation, which may reverse neurodegeneration and enhance patients' quality of life [8] Company Overview - Annovis Bio Inc. is focused on developing therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's disease, and is headquartered in Malvern, Pennsylvania [9]

Core Viewpoint - Annovis Bio Inc. has initiated a pivotal Phase 3 study for its drug candidate, buntanetap, aimed at treating early Alzheimer's disease, marking a significant step towards market approval and addressing the needs of millions of patients [1][2]. Study Details - The Phase 3 trial is a randomized, placebo-controlled, double-blind study designed to assess the safety and efficacy of a daily dose of buntanetap over 18 months, with a 6-month symptomatic assessment followed by a 12-month evaluation of potential disease-modifying effects [3]. - The study protocol received FDA approval based on positive results from previous trials, which indicated significant cognitive improvement in a subgroup of early AD patients without safety concerns [3]. Financial Aspects - The company recently completed a public offering of 5,250,000 units, generating gross proceeds of $21 million, which will fund the initial 6-month portion of the study, with additional capital expected from warrant exercises for the 12-month phase [4]. Participant Enrollment - Annovis plans to enroll over 750 participants across approximately 100 sites in the United States, with the first two sites already recruiting patients [7]. Drug Mechanism - Buntanetap is an orally available molecule that targets neurodegeneration by inhibiting neurotoxic protein aggregation, improving axonal transport, synaptic transmission, and reducing neuroinflammation, potentially reversing neurodegeneration and enhancing patients' quality of life [8]. Company Overview - Annovis Bio Inc. is focused on developing therapies for neurodegenerative diseases, including Alzheimer's and Parkinson's disease, and is headquartered in Malvern, Pennsylvania [9].

MALVERN, PA, Feb. 04, 2025 (GLOBE NEWSWIRE) -- via IBN - Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the closing of its previously announced underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4. ...

MALVERN, Pa., Feb. 03, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE:ANVS) ("Annovis" or the "Company"), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer's disease (AD) and Parkinson's disease (PD), today announced the pricing of an underwritten public offering of 5,250,000 shares of common stock and warrants to purchase 5,250,000 shares of common stock at a combined public offering price of $4.00 per share. The war ...

MALVERN, Pa., Jan. 31, 2025 (GLOBE NEWSWIRE) -- via IBN – Annovis Bio, Inc. (NYSE: ANVS) (“Annovis” or the “Company”), a late-stage clinical drug platform company pioneering transformative therapies for neurodegenerative diseases such as Alzheimer’s disease (AD) and Parkinson’s disease (PD), today announced that it intends to offer to sell common stock and warrants in an underwritten public offering. All of the common stock and warrants are to be sold by the Company. ThinkEquity is acting as sole book-runn ...